Dexmedetomidine for Continuous Sedation
A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland
- Helsinki University Hospital
-
Kuopio, Finland
- Kuopio University Hospital
-
Tampere, Finland
- Tampere University Hospital
-
-
-
-
-
Bern, Switzerland
- Inselspital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical need for sedation and mechanical ventilation
- Receiving full intensive care life support
- Expected stay in ICU of at least 48 hours (h) from time of admission
- Expected requirement for sedation of at least 24h from time of randomisation
- Written informed consent within 36h of ICU admission
Exclusion Criteria:
- Acute severe neurological disorder
- Acute uncompensated circulatory failure at time of randomisation
- Severe bradycardia
- Atrioventricular (AV) conduction block (II-III) unless pacemaker fitted
- Severe hepatic impairment
- Need for muscle relaxation at time of randomisation
- Loss of hearing or vision or any condition interfering significantly with RASS assessment
- Positive pregnancy test or currently lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Proportion of time during sedative infusion with a Richmond Agitation Sedation Scale (RASS) score within the individually-prescribed target range
|
|
Time from ICU admission to discharge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Nurse's assessment of subject communication
|
|
Duration of mechanical ventilation, weaning time and ventilator-free days in ICU
|
|
Length of total hospital stay
|
|
Functional recovery during hospitalisation
|
|
Need for rescue medication to maintain sedation
|
|
Frequency of delirium
|
|
Frequency of organ failures and failure-free days
|
|
Frequency of critical illness polyneuropathy
|
|
ICU- and in-hospital survival
|
|
Cost of care in the ICU
|
|
Total cost of hospitalisation
|
|
Blood levels of dexmedetomidine seen with long-term treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jukka Takala, MD, PhD, University/University Hospital, Bern, Switzerland
- Principal Investigator: Esko Ruokonen, MD, PhD, Kuopio University Hospital, Finland
- Principal Investigator: Stephan Jakob, MD, PhD, University Hospital, Bern, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
Other Study ID Numbers
- 3005011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.